Companies /Healthcare

Regeneron Pharmaceuticals Inc

NASDAQ: REGN Biotechnology
$794.19
▼ $13.52 (−1.67%) today
Markets closed · 3:40am ET

REGN Coverage

Page 11
12:05pm ET
Health and Healthcare

Regeneron Scores Win in Late-Stage Rheumatoid Arthritis Trial

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 monotherapy study…

Chris Lange
9:05am ET
Health and Healthcare

Regeneron Falls on Missed Earnings

Regeneron Pharmaceuticals reported disappointing fourth-quarter financial results before the markets opened on Tuesday.

Chris Lange
11:53am ET
Health and Healthcare

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct to diet…

Chris Lange